HeartBeam, Inc. BEAT
0.40 USD -0.01 (-2.03%)
At closeNov 13, 2026, 7:23 PM EST
0.38 -0.02 -5.13%
After hours · Nov 13, 7:23 PM ET
0.363 Day range 0.4046
0.36 52-week range 3.44
- YTD
- -83.52%
- 1 year
- -74.81%
News
seekingalpha.com HeartBeam, Inc. (BEAT) Q3 2026 Earnings Call Transcript HeartBeam, Inc. (BEAT) Q3 2026 Earnings Call Transcript
benzinga.com HeartBeam Q3 EPS $(0.05) Beats $(0.09) Estimate HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 66.67 percent increase over losses of $(0.15)…
businesswire.com HeartBeam Reports Third Quarter 2026 Results SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Third Quarter 2026 Results.
businesswire.com HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time.
businesswire.com HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to be as Accurate as Standard 12-Lead ECG.
businesswire.com HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026 SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026.
benzinga.com HeartBeam Wins FDA Total Product Life Cycle Advisory Program Pilot Acceptance For Heart Attack Assessment Technology Acceptance into FDA’s TAP Pilot follows Breakthrough Device Designation granted earlier this month for HeartBeam’s heart attack assessment technologyTAP Pilot provides dedicated FDA advisors and…
benzinga.com HeartBeam Completes Enrollment Ahead Of Schedule In 486-Patient HEADSTART-ACS Study HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million…
businesswire.com HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology SANTA CLARA, Calif.--(BUSINESS WIRE)--HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology.- benzinga.com HeartBeam Named Contributing Partner In Launch Of EXIT-CVD Research Project, Co-Funded By European Union Innovative Health Initiative And Industry Partners HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22…
businesswire.com HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock…
benzinga.com HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System Medical technology provider HeartBeam, Inc. (NASDAQ:BEAT) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home cardiac assessment tool.
benzinga.com HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
benzinga.com Dow Gains 100 Points; ISM Services PMI Falls In September U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.
benzinga.com US Stocks Mixed; Nasdaq Gains Over 50 Points U.S. stocks mixed: Nasdaq and S&P 500 rose while Dow dipped. Weak jobs data pressured outlook; oil fell, while gold, silver and copper gained.
benzinga.com HeartBeam Receives FDA Breakthrough Device Designation For Its HeartBeam System For Assessing Potential Heart Attacks At Home The designation recognizes the potential of HeartBeam’s 3D ECG technology, which captures the heart’s electrical signals from three non-coplanar dimensions, to enable physicians to evaluate signs of…
businesswire.com HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.
defenseworld.net HeartBeam, Inc. (NASDAQ:BEAT) Stock Has Consensus Price Target of $4.00 HeartBeam, Inc. (NASDAQ: BEAT - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the company, MarketBeat Ratings reports. One…
businesswire.com HeartBeam, Inc. Letter to Shareholders SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. Letter to Shareholders.- benzinga.com HeartBeam Enters ATM Equity Offering Agreement To Sell Up To $25M Of Common Stock Through Titan Partners Securities On August 14, 2026, HeartBeam, Inc. (the "Company"), entered into an At-The-Market Equity Offering Sales Agreement (the "Sales Agreement") with Titan Partners Securities LLC, as sales agent, pursuant…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
seekingalpha.com HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript
benzinga.com HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript HeartBeam (NASDAQ:BEAT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
businesswire.com HeartBeam Reports Second Quarter 2026 Results SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.
businesswire.com HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.
zacks.com Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.- benzinga.com Maxim Group Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $2 Maxim Group analyst Anthony Vendetti initiates coverage on HeartBeam (NASDAQ:BEAT) with a Buy rating and announces Price Target of $2.
gurufocus.com HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device [url="]HeartBeam, Inc.[/url] (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today an- benzinga.com HeartBeam Wins U.S. Patent Expanding ECG Device With Acoustic Sensing, Impedance Features For Heart Disease Monitoring Patent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilitiesAcoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve…
zacks.com Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.
businesswire.com HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule.
benzinga.com HeartBeam Announces Reorganization To Prioritize Global Market Reach And Capital Efficiency While Accelerating Execution; To License Its 3D ECG Signal Technology To Established Partners Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device salesAdvancing toward heart attack detection as a key expansion of the platformTailoring…
businesswire.com HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition.
gurufocus.com HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home [url="]HeartBeam, Inc.[/url] (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today an
benzinga.com HeartBeam Publishes JACC Study Showing Its Credit Card‑Sized ECG Device Can Predict Heart Attack Risk In Chest Pain Patients Publication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack riskStudy advances the…- benzinga.com HC Wainwright & Co. Maintains Buy on HeartBeam, Lowers Price Target to $2.5 HC Wainwright & Co. analyst Yi Chen maintains HeartBeam (NASDAQ:BEAT) with a Buy and lowers the price target from $5.5 to $2.5.
- benzinga.com Benchmark Maintains Speculative Buy on HeartBeam, Lowers Price Target to $5 Benchmark analyst Bill Sutherland maintains HeartBeam (NASDAQ:BEAT) with a Speculative Buy and lowers the price target from $8 to $5.
benzinga.com HeartBeam Q1 2026 Earnings Call: Complete Transcript - benzinga.com HeartBeam Q1 EPS $(0.12) Beats $(0.14) Estimate HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 33.33 percent increase over losses of $(0.18)…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com HeartBeam Initiates Pilot Study Of Its Novel 12-Lead ECG Patch In Patients With Suspected Coronary Artery Disease The study is being conducted at two leading hospitals in Belgrade, Serbia. The initiation of the pilot study represents a significant step in the development of the HeartBeam patch which has the…
benzinga.com HeartBeam Enters Commercial Agreement With Atelier Health To Expand The Company's Commercial Footprint Across Four Targeted Launch Markets Leading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patientsOpens up flagship sites across New York, Dallas, South Florida and…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-year guidance. Other gainers include NICM, AGAE, IMMP, LIMN, CIIT, MLSS, LAES, GBR, and STNE. Losers…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com B. Riley Securities Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $4 B. Riley Securities analyst Anderson Schock initiates coverage on HeartBeam (NASDAQ:BEAT) with a Buy rating and announces Price Target of $4.
benzinga.com This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See others' views on these stocks.